• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Research Brief on 3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide (CAS: 1211364-66-7): Recent Advances and Applications

3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide (CAS: 1211364-66-7) is a heterocyclic compound that has garnered significant attention in the field of medicinal chemistry due to its potential pharmacological properties. Recent studies have explored its applications as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of antimicrobial, anticancer, and anti-inflammatory agents. This research brief synthesizes the latest findings on this compound, highlighting its synthetic pathways, biological activities, and potential therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide as a precursor in the synthesis of imidazopyridine-based kinase inhibitors. The study revealed that derivatives of this compound exhibited potent inhibitory activity against specific tyrosine kinases implicated in cancer progression, with IC50 values in the nanomolar range. Molecular docking studies further elucidated the binding interactions of these derivatives with target kinases, providing a structural basis for their activity.

In addition to its anticancer potential, recent research has explored the antimicrobial properties of 3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide. A 2024 publication in Bioorganic & Medicinal Chemistry Letters reported that hydrazide derivatives of this compound displayed broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, as confirmed through mechanistic assays and electron microscopy.

The synthetic accessibility of 3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide has also been a focus of recent investigations. A 2023 paper in Organic Process Research & Development described an optimized, scalable synthesis route for this compound, achieving a 78% yield with high purity (>99%). This advancement addresses previous challenges related to low yields and cumbersome purification steps, facilitating its broader application in drug discovery programs.

Ongoing research is exploring the compound's potential in neurodegenerative diseases. Preliminary in vitro studies suggest that certain derivatives may modulate neuroinflammatory pathways, though further in vivo validation is required. The compound's unique scaffold offers versatility for structural modifications, enabling the development of targeted therapies for diverse indications.

In conclusion, 3-Chloroimidazo[1,2-a]pyridine-6-carbohydrazide (CAS: 1211364-66-7) represents a promising scaffold in medicinal chemistry, with demonstrated applications in oncology, infectious diseases, and potentially CNS disorders. Continued research into its structure-activity relationships and mechanism of action will likely yield additional therapeutic candidates in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)